title: Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
abstract: Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.
authors.forename: Shaji K
authors.initials: SK
authors.lastname: Kumar
authors.forename: Natalie S
authors.initials: NS
authors.lastname: Callander
authors.forename: Melissa
authors.initials: M
authors.lastname: Alsina
authors.forename: Djordje
authors.initials: D
authors.lastname: Atanackovic
authors.forename: J Sybil
authors.initials: JS
authors.lastname: Biermann
authors.forename: Jason C
authors.initials: JC
authors.lastname: Chandler
authors.forename: Caitlin
authors.initials: C
authors.lastname: Costello
authors.forename: Matthew
authors.initials: M
authors.lastname: Faiman
authors.forename: Henry C
authors.initials: HC
authors.lastname: Fung
authors.forename: Cristina
authors.initials: C
authors.lastname: Gasparetto
authors.forename: Kelly
authors.initials: K
authors.lastname: Godby
authors.forename: Craig
authors.initials: C
authors.lastname: Hofmeister
authors.forename: Leona
authors.initials: L
authors.lastname: Holmberg
authors.forename: Sarah
authors.initials: S
authors.lastname: Holstein
authors.forename: Carol Ann
authors.initials: CA
authors.lastname: Huff
authors.forename: Adetola
authors.initials: A
authors.lastname: Kassim
authors.forename: Michaela
authors.initials: M
authors.lastname: Liedtke
authors.forename: Thomas
authors.initials: T
authors.lastname: Martin
authors.forename: James
authors.initials: J
authors.lastname: Omel
authors.forename: Noopur
authors.initials: N
authors.lastname: Raje
authors.forename: Frederic J
authors.initials: FJ
authors.lastname: Reu
authors.forename: Seema
authors.initials: S
authors.lastname: Singhal
authors.forename: George
authors.initials: G
authors.lastname: Somlo
authors.forename: Keith
authors.initials: K
authors.lastname: Stockerl-Goldstein
authors.forename: Steven P
authors.initials: SP
authors.lastname: Treon
authors.forename: Donna
authors.initials: D
authors.lastname: Weber
authors.forename: Joachim
authors.initials: J
authors.lastname: Yahalom
authors.forename: Dorothy A
authors.initials: DA
authors.lastname: Shead
authors.forename: Rashmi
authors.initials: R
authors.lastname: Kumar
mesh_terms: D000970:Antineoplastic Agents / Q000600:supply & distribution / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000592:standards / Q000627:therapeutic use*; D058070:Asymptomatic Diseases; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000592:standards; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D008279:Magnetic Resonance Imaging; D060046:Maintenance Chemotherapy / Q000379:methods / Q000592:standards; D008495:Medical Oncology / Q000592:standards*; D009101:Multiple Myeloma / Q000097:blood / Q000175:diagnosis* / Q000628:therapy*; D009194:Myeloma Proteins / Q000032:analysis; D000072078:Positron Emission Tomography Computed Tomography; D018714:Radiotherapy, Adjuvant / Q000379:methods / Q000592:standards; D012698:Serologic Tests; D059039:Standard of Care; D033581:Stem Cell Transplantation / Q000379:methods* / Q000592:standards; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007136:Immunoglobulins; D009194:Myeloma Proteins; C085016:multiple myeloma M-proteins